联合检测可溶性ST2与氨基末端B型利钠肽前体可早期评估急性冠脉综合征合并心源性休克的严重程度
CardShock研究(NCT01374867)是一项前瞻性欧洲多国研究,纳入9家三级大学医院中由急性冠脉综合征所致心源性休克患者145例,在ICU或心脏监护病房期间8个时间点检测血浆可溶性ST2与氨基末端B型利钠肽前体。两者联合对30天死亡的判别能力从休克发作后12小时的曲线下面积0.77升至5-10天的0.93。12小时时两者均升高(可溶性ST2≥500 ng/mL且氨基末端B型利钠肽前体≥4500 ng/L)者30天死亡率为79%,仅一项升高者为31%,均不升高者为10%(p<0.001)。12小时联合检测在CardShock风险评分基础上可正确重分类11%的患者。
要点
- 12小时时可溶性ST2≥500 ng/mL且氨基末端B型利钠肽前体≥4500 ng/L者30天死亡率为79%,仅一项升高者为31%,均不升高者为10%(p<0.001)。
- 可溶性ST2与氨基末端B型利钠肽前体联合对30天死亡的曲线下面积从12小时的0.77升至5-10天时的0.93。
- 12小时联合检测在CardShock风险评分基础上可正确重分类11%的患者。
- CardShock风险评分由基线7个临床变量计算,与短期死亡率相关。
适用人群与场景
- 由急性冠脉综合征所致心源性休克患者(n=145),来自9家三级大学医院。
诊断标准与关键阈值
- 12小时时两标志物均升高定义为可溶性ST2≥500 ng/mL且氨基末端B型利钠肽前体≥4500 ng/L。
研究设计与关键结果
- CardShock为前瞻性欧洲多国研究,本亚组分析145例急性冠脉综合征相关心源性休克患者,在ICU或心脏监护病房期间8个时间点检测血浆标志物。
- 可溶性ST2与氨基末端B型利钠肽前体联合对30天死亡的曲线下面积从12小时的0.77升至5-10天时的0.93。
- 12小时时两标志物均升高者30天死亡率为79%,仅一项升高者为31%,均不升高者为10%(p<0.001)。
- 12小时联合检测在CardShock风险评分基础上可正确重分类11%的患者。
证据类型、等级与局限
- 证据类型:前瞻性欧洲多国研究(CardShock,NCT01374867)的亚组分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对急性冠脉综合征相关心源性休克患者,12小时联合检测可溶性ST2与氨基末端B型利钠肽前体可提供超越临床变量的早期风险评估,作者认为可能有助于这些患者的治疗决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Mortality in cardiogenic shock complicating acute coronary syndrome is high, and objective risk stratification is needed for rational use of advanced therapies such as mechanical circulatory support. Traditionally, clinical variables have been used to judge risk in cardiogenic shock. The aim of this study was to assess the added value of serial measurement of soluble ST2 and amino-terminal pro-B-type natriuretic peptide to clinical parameters for risk stratification in cardiogenic shock.
DESIGN: CardShock (www.clinicaltrials.gov NCT01374867) is a prospective European multinational study of cardiogenic shock. The main study introduced CardShock risk score, which is calculated from seven clinical variables at baseline, and was associated with short-term mortality.
SETTING: Nine tertiary care university hospitals.
PATIENTS: Patients with cardiogenic shock caused by acute coronary syndrome (n=145).
INTERVENTIONS: In this substudy, plasma samples from the study patients were analyzed at eight time points during the ICU or cardiac care unit stay. Additional prognostic value of the biomarkers was assessed with incremental discrimination improvement.
MEASUREMENTS AND MAIN RESULTS: The combination of soluble ST2 and amino-terminal pro-B-type natriuretic peptide showed excellent discrimination for 30-day mortality (area under the curve, 0.77 at 12 hr up to 0.93 at 5-10 d after cardiogenic shock onset). At 12 hours, patients with both biomarkers elevated (soluble ST2, ≥ 500 ng/mL and amino-terminal pro-B-type natriuretic peptide, ≥ 4,500 ng/L) had higher 30-day mortality (79%) compared to those with one or neither biomarkers elevated (31% or 10%, respectively; p < 0.001). Combined measurement of soluble ST2 and amino-terminal pro-B-type natriuretic peptide at 12 hours added value to CardShock risk score, correctly reclassifying 11% of patients.
CONCLUSIONS: The combination of results for soluble ST2 and amino-terminal pro-B-type natriuretic peptide provides early risk assessment beyond clinical variables in patients with acute coronary syndrome-related cardiogenic shock and may help therapeutic decision making in these patients.
参考来源
- Tolppanen H, Rivas-Lasarte M, Lassus J, et al. Combined Measurement of Soluble ST2 and Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome. Crit Care Med. 2017. PMID: 28403119. doi:10.1097/CCM.0000000000002336
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。